# Zero-shot prediction of drug responses using biologically informed neural networks trained on phosphoproteomic timeseries

**Authors:** Konstantinos Antonopoulos, Olof Nordenstorm, Avlant Nilsson

PMC · DOI: 10.1371/journal.pcbi.1014100 · PLOS Computational Biology · 2026-03-18

## TL;DR

A new neural network model predicts drug effects on cell signaling without prior training on specific drugs, using biological knowledge and phosphoproteomic data.

## Contribution

A biologically informed neural network framework that enables zero-shot prediction of drug-induced phosphoproteomic responses.

## Key findings

- The model accurately predicts unseen drug responses and outperforms baseline methods.
- It identifies both canonical and non-canonical signaling effects, including cross-pathway drug impacts.

## Abstract

Cellular signaling is driven by complex, dynamic phosphorylation networks that control growth and survival, and their dysregulation underlies diseases such as cancer. Although modern mass spectrometry enables large-scale quantification of phosphoproteomic responses over time, these measurements remain descriptive and cannot by themselves predict how signaling will evolve under perturbations. Here, we extend a biologically informed recurrent neural network framework (LEMBAS), to learn time-resolved phosphoproteomic trajectories. We introduce two interpretable modules; a phosphosite mapping that links signaling nodes to measured phosphorylation sites and a monotonic time mapping that aligns continuous experimental times to discrete signaling steps. Using synthetic benchmarks and an EGF-stimulation dataset with inhibitor treatments, the model accurately interpolates unseen time points and predicts drug-induced phosphoproteomic responses in a zero-shot setting, outperforming naïve and fully connected baselines. Importantly, the model identifies both canonical and non-canonical signaling effects, including modulation of the transcription factor FOXO3:S7 (from the PI3K/AKT pathway) by drugs affecting PTPN11 (from the RAS/ERK pathway). By combining mechanistic priors with deep learning, our framework provides a scalable approach to interpret and predict dynamic drug responses from phosphoproteomic data.

Cells constantly adjust their behavior in response to signals from their environment, and many drugs work by altering these communication networks. Measuring these changes directly is expensive and time-consuming, so we set out to build a computer model that can make accurate predictions without needing new experiments for each drug. We trained a neural network using large datasets that track protein modifications over time after cells are stimulated. The model uses prior biological knowledge about how proteins interact, allowing it to connect molecular events to drug effects. Remarkably, it can make “zero-shot” predictions; that is, it can predict the effect of drugs it has never seen before. We show that the model can capture both expected and surprising drug responses, and it can even suggest new links between signaling proteins. Our approach demonstrates how combining biological knowledge with modern machine learning can improve the prediction of cellular responses and may ultimately accelerate drug discovery and personalized medicine.

## Linked entities

- **Genes:** PTPN11 (protein tyrosine phosphatase non-receptor type 11) [NCBI Gene 5781], FOXO3 (forkhead box O3) [NCBI Gene 2309]
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, MAP2K2 (mitogen-activated protein kinase kinase 2) [NCBI Gene 5605] {aka CFC4, MAPKK2, MEK2, MKK2, PRKMK2}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, FOXO3 (forkhead box O3) [NCBI Gene 2309] {aka AF6q21, FKHRL1, FKHRL1P2, FOXO2, FOXO3A}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, PKN1 (protein kinase N1) [NCBI Gene 5585] {aka DBK, PAK-1, PAK1, PKN, PKN-ALPHA, PRK1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, PTPN11 (protein tyrosine phosphatase non-receptor type 11) [NCBI Gene 5781] {aka BPTP3, CFC, JMML, METCDS, NS1, PTP-1D}, PIK3CD (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta) [NCBI Gene 5293] {aka APDS, IMD14, IMD14A, IMD14B, P110DELTA, PI3K}, RPS6KA1 (ribosomal protein S6 kinase A1) [NCBI Gene 6195] {aka HU-1, MAPKAPK1, MAPKAPK1A, RSK, RSK1, p90Rsk}, MAP2K1 (mitogen-activated protein kinase kinase 1) [NCBI Gene 5604] {aka CFC3, MAPKK1, MEK1, MEL, MKK1, PRKMK1}, GAB1 (GRB2 associated binding protein 1) [NCBI Gene 2549] {aka DFNB26}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** Cancer (MESH:D009369)
- **Chemicals:** doxorubicin (MESH:D004317), phosphosite (-), LY294002 (MESH:C085911), DMSO (MESH:D004121), SHP099 (MESH:C000609471)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MCF10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), SL0101 — Homo sapiens (Human), Transformed cell line (CVCL_K371), U0126 — Homo sapiens (Human), Transformed cell line (CVCL_K395), SHP099 — Gallus gallus (Chicken), Chicken bursal lymphoma, Cancer cell line (CVCL_2G92)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13035234/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13035234/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC13035234/full.md

---
Source: https://tomesphere.com/paper/PMC13035234